ChemDiv Marks a Milestone as Orionis Biosciences’ Novel Immunotherapy Enters Phase I Clinical Trials
ChemDiv CEO, Bill Farley. "This marks a significant step in harnessing intrinsic immunobiology pharmacologically, and we are excited about the potential impact it may have on revolutionizing cancer therapeutics."